amr industry alliance
The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.
read moreWe drive and measure the life-sciences industry progress to curb antimicrobial resistance in four different areas:
shared goals
We are uniting efforts to reduce the development of antimicrobial resistance, invest in R&D to meet public health needs and improve access to antibiotics, vaccines and diagnostics.
progress report
In 2018, the Alliance published its first progress report that provides unique insights into the practical steps its members are taking to respond to AMR. The findings of the report illustrate both the challenges the healthcare sector faces in tackling AMR and how the industry is essential to winning this battle.
in action
Our case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps we are taking to invest in new research to develop new antibiotics and vaccines, prevent infection ,and improve appropriate use of antibiotics.
latest news
New brochure to discover the AMR Industry Alliance in 2 minutes
Representing more than 100 biotechnology, diagnostics, generics and research-based pharmaceutical companies and associations, the AMR Industry Alliance is one of the largest private sector coalitions...
Read more
AMR Industry Alliance Round-Up, Issue No.1, June 2019
This is the first issue of "Alliance Round-Up" written for the more than 100 biotech, diagnostic, generic and pharma companies who are members of the AMR Industry Alliance, as well as people...
Read more
The largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all stakeholders
The largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all st...
Read moreamr in numbers
AMR Impact
Life-sciences at the forefront of the battle against AMR
Development of National Action Plans
R&D
Biotechs
Diagnostics
from the blog
The new reality for next-gen antibiotics
The future of antibiotic development lies in targeted approaches that can deliver novel drugs tailored to tackle those highly resistant pathogens with greatest medical need. The world of antibacterial therapy as we know it is changing fast. For decades we have used antibiotics empirically, treat...
Read more view all
